HELP — Cybin Inc. Common Stock
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Cybin Inc. Common Stock
XNAS
Healthcare · Biotechnology
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Price & today
$12.37
ATR(14) 1.02 (8.21%)
| Stock today | -11.77% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -11.52% |
Sector correlation
| 20-day correlation with XLV | 0.21 |
| 60-day correlation with XLV | 0.15 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $13.01 |
| 20 EMA | $12.57 |
| 50 EMA | $10.84 |
| EMA stack | BULLISH |
| RSI(14) | 51.4 |
| 52-week high distance | -13.80% |
| 52-week low distance | +228.99% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | — |
| Sector rank | — |
| Next earnings | 2026-11-12 (TNS, 54d) |
MarketSmith metrics - our compute
RS Rating
96.7
ADR%
8.2
RMV (tight)
100.0
Ext (ATR>20EMA)
-0.2
Rel Vol
302.0%
U/D 50d
1.84
U/D 25d
1.49
Accum/Dist 25d
7 / 2
EPS YoY
-
LoD dist
27.0
Off 52w High
18.3%
Above 52w Low
229.0%
1W / 1M
-4.6 / +5.0
Avg $Vol 50d
19.9M
Mkt Cap (B)
0.8
Trend 8/8
YES
Leads Group
YES
Sector XLV
+1.8% 1W
not available: eps_history(<5 quarters), revenue(no EDGAR qtrs=1 fact)
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
223.8
Profit margin
0.0%
ROE
-86.9%
Debt/Equity
-
Rev growth
-
Analyst target
$41 (+234%)
Analyst rating
STRONG_BUY
Institutional %
43.7%
Insider %
11.2%
Float %
179.2%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
57 / 147
Industry
Biotechnology
Float
111.1M
Float turnover 20d
1.6%
Avg $Vol 20d / 50d
23.5M / 19.9M
Days to cover
1.6
Short % float
-
Institutional %
43.7%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 · Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket Benzinga
- Sep 16 · Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
- Sep 16 · Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript SeekingAlpha
- Sep 10 · Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York GlobeNewsWire
- Sep 10 · Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York Yahoo
- Sep 10 · Top 3 Health Care Stocks That Are Ticking Portfolio Bombs Benzinga
- Sep 09 · Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York GlobeNewsWire
- Sep 03 · Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York GlobeNewsWire